01 / IDENTITY
Compound Profile
ORIGIN
Synthetic analogue of human GLP-1 (glucagon-like peptide-1), modified with a C18 fatty diacid chain via a linker to human albumin. Developed by Novo Nordisk. Approved as Ozempic (diabetes, 2017) and Wegovy (obesity, 2021).
MECHANISM
Binds and activates GLP-1R (glucagon-like peptide-1 receptor) — expressed in pancreas, brain, GI tract, heart, and kidneys. Mimics the natural incretin hormone GLP-1 with 94% structural homology but ~168× longer half-life due to albumin binding.
PRIMARY ACTIONS
① Glucose-dependent insulin secretion (lowers blood sugar only when elevated — no hypoglycemia risk at therapeutic doses) ② Suppresses glucagon ③ Slows gastric emptying ④ Central appetite suppression via hypothalamic GLP-1R
WHY WEEKLY DOSING
The fatty acid chain binds to albumin in the bloodstream, dramatically extending half-life from 2 min (native GLP-1) to ~7 days. This makes once-weekly subcutaneous injection sufficient for stable plasma levels.
CARDIOVASCULAR PROTECTION
SUSTAIN-6 and SELECT trials: semaglutide reduces major adverse cardiovascular events (MACE) by 20–26% in high-risk populations. Mechanism: direct cardiac GLP-1R signaling + indirect effects of weight loss and glucose normalization.
COMPOUNDING NOTE
Compounded semaglutide (base form, not salt) from 503A/503B pharmacies is identical in mechanism to branded products. Dose-equivalent to Ozempic/Wegovy when reconstituted correctly.
02 / RESEARCH HISTORY
Development Timeline
1987
GLP-1 identified as a natural incretin hormone by Mojsov et al. at Rockefeller University. The core biology of the GLP-1 receptor axis is established.
2000s
Novo Nordisk develops semaglutide as an improved GLP-1 analogue — targeting the albumin binding approach to achieve weekly dosing and superior receptor affinity vs. earlier GLP-1 agents (exenatide, liraglutide).
2017
FDA approval of Ozempic (0.5mg/1mg/2mg) for Type 2 Diabetes. SUSTAIN trial series: superior HbA1c reduction versus comparators, unexpected significant weight loss observed.
2021
FDA approval of Wegovy (2.4mg) for chronic weight management — first drug approved for obesity in a decade. STEP 1 trial: 14.9% mean body weight reduction vs. 2.4% placebo at 68 weeks.
2023
SELECT trial published in NEJM: semaglutide 2.4mg reduces major cardiovascular events by 20% in non-diabetic obese adults. FDA approves cardiovascular risk reduction indication. Global shortage of branded product drives compounding pharmacy demand.
2024–Present
Oral semaglutide (Rybelsus) gains traction. Tirzepatide and Retatrutide emerge as dual/triple agonists outperforming semaglutide on weight loss. Semaglutide remains the most studied GLP-1 agent with the longest safety record.
03 / BENEFITS & MECHANISMS
Research-Supported Effects
01
Weight Loss — 15–16% at Full Dose
STEP 1 trial (2021): 14.9% mean weight loss at 2.4mg/week × 68 weeks vs. 2.4% placebo. Mechanism: central appetite suppression via hypothalamic GLP-1R reduces caloric intake 30–40%. Gastric emptying slowed — prolonged satiety after meals. Patients report dramatically reduced food noise and cravings.
02
Blood Sugar Control — HbA1c Reduction 1.5–2.2%
Glucose-dependent insulin secretion: only releases insulin when blood sugar is elevated — mechanistically prevents hypoglycemia at therapeutic doses. Suppresses postprandial glucagon spike. SUSTAIN trials: 1.5–2.2% HbA1c reduction, superior to DPP-4 inhibitors, SGLT2 inhibitors, and basal insulin comparators.
03
Cardiovascular Protection — 20% MACE Reduction
SELECT trial (2023): 20% reduction in MACE (myocardial infarction, stroke, CV death) in 17,600 non-diabetic obese adults. Direct cardiac GLP-1R signaling provides cardioprotection independent of weight loss. FDA approved cardiovascular indication — a landmark for any weight loss medication.
04
Liver Protection — NASH/NAFLD Improvement
ESSENCE trial (2024): semaglutide achieves NASH resolution in 62.9% of patients at 72 weeks. Reduces liver fat (MRI-PDFF), inflammation, and fibrosis. First drug to show significant anti-fibrotic effects in non-alcoholic steatohepatitis — FDA approval pending for this indication.
05
Kidney Protection — CKD Progression Slowed
FLOW trial (2024): 24% reduction in kidney disease progression and 20% reduction in CV death in CKD patients. GLP-1R expressed in kidney — direct renoprotective signaling plus indirect effects of glucose and blood pressure normalization.
04 / RECONSTITUTION
Vial Preparation
COMPOUNDED SEMAGLUTIDE — TYPICAL VIAL SIZES: 2mg, 4mg, 5mg, 10mg
Standard: Add 2.0 mL (200 units) bacteriostatic water to a 2mg vial
Concentration: 0.01 mg per unit (10 mcg per unit)
| DOSE | mg | UNITS ON SYRINGE | VOLUME |
|---|
| STARTING |
0.25mg |
25 units |
0.25 mL |
| STEP 2 |
0.5mg |
50 units |
0.50 mL |
| STEP 3 |
1.0mg |
100 units |
1.0 mL |
| TARGET |
2.4mg (Wegovy dose) |
Requires 4–5mg vial reconstituted at appropriate concentration |
Per provider prescription |
⚠ Concentration Varies by Pharmacy: Compounding pharmacies vary in vial concentration. ALWAYS confirm the exact mg/mL concentration on your pharmacy label before drawing dose. Recalculate units every time you open a new vial. Do not assume concentrations are consistent across suppliers.
Storage: Reconstituted semaglutide: refrigerate (2–8°C), use within 28 days. Protect from light. Once-weekly injection — each vial should last several weeks at standard escalation doses.
05 / DOSE ESCALATION PROTOCOL
Standard Escalation Schedule
Why Escalation Matters: Semaglutide must be titrated slowly to minimize GI side effects (nausea, vomiting). Starting too high causes intolerable nausea and high discontinuation rates. The escalation schedule allows GI receptors to adapt. Most patients reach their maintenance dose at weeks 16–20.
| WEEKS | DOSE | FREQUENCY | EXPECTED RESPONSE |
|---|
| 1–4 |
0.25 mg |
Once weekly SC |
Mild appetite reduction, minimal GI effects. Body adapting. |
| 5–8 |
0.5 mg |
Once weekly SC |
Noticeable appetite reduction, some nausea possible. 2–4% weight loss. |
| 9–12 |
1.0 mg |
Once weekly SC |
Significant appetite suppression. 5–8% weight loss typical by week 12. |
| 13–16 |
1.7 mg |
Once weekly SC |
Strong food noise suppression. Weight loss accelerates. Diabetes patients may reach HbA1c target. |
| 17+ |
2.4 mg |
Once weekly SC (maintenance) |
Maximum approved dose for obesity. 15%+ weight loss at 68 weeks in STEP trials. |
Stall Management: Weight loss often plateaus at weeks 8–12 as body adapts. This is a hormonal adjustment phase — do not stop. Dose escalation typically breaks the plateau. Adding AOD-9604 500mcg/day or MOTS-c 5mg/day to the protocol can augment fat mobilization during plateau phases.
06 / TIMING & ADMINISTRATION
Injection Protocol
FREQUENCY
Once Weekly — Same Day Each Week
TIMING RELATIVE TO FOOD
No fasting required. Can inject any time of day. Most patients prefer a consistent weekly day (e.g., every Sunday AM). Injecting the night before social eating events can time peak appetite suppression effect.
INJECTION SITES
Subcutaneous — abdomen (preferred), outer thigh, or upper arm. Rotate sites weekly. Abdomen provides most consistent absorption. Avoid injecting within 2 inches of navel.
GI SIDE EFFECT MANAGEMENT
Nausea peaks 8–12 hours post-injection, resolves within 24–48 hours. Strategies: ① Inject before bed — sleep through peak nausea window ② Eat small, low-fat meals on injection day ③ Avoid alcohol for 24h post-injection ④ Ginger tea, ondansetron (Zofran) PRN for acute nausea
MISSED DOSE
If <5 days since missed dose — inject as soon as possible. If ≥5 days — skip and resume on next scheduled day. Do NOT double-dose. Maintain regular weekly schedule.
07 / BIOMARKER MONITORING
Recommended Lab Panel
METABOLIC — PRIMARY RESPONSE
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| HbA1chemoglobin A1c |
CLINICAL<5.7% |
OPTIMAL<5.3% |
Primary T2DM response marker. Recheck at 12 weeks. Expect 1.5–2.2% reduction from baseline in diabetic patients. |
| Fasting Glucoseblood glucose |
CLINICAL70–99 mg/dL |
OPTIMAL72–90 mg/dL |
Should improve progressively. Glucose-dependent mechanism = minimal hypoglycemia risk as monotherapy. |
| Fasting Insulin + HOMA-IRinsulin resistance index |
CLINICALHOMA-IR <2.5 |
OPTIMALHOMA-IR <1.5 |
Insulin sensitivity improves with weight loss. Track trajectory every 12 weeks. |
| Lipid Paneltotal cholesterol, LDL, HDL, TG |
CLINICALStandard |
OPTIMALTG <80 / LDL <70 mg/dL |
TG and LDL improve significantly with weight loss. HDL rises. Recheck at 12–16 weeks. |
SAFETY MONITORING
| MARKER | CLINICAL RANGE | NOTES |
|---|
| Amylase / Lipasepancreatic enzymes |
CLINICALStandard |
Baseline + annually. Rare pancreatitis risk — if severe abdominal pain develops, hold semaglutide and check immediately. |
| Thyroid (TSH)thyroid-stimulating hormone |
CLINICAL0.5–4.5 mIU/L |
Semaglutide carries MTC (medullary thyroid carcinoma) warning in rodents — not confirmed in humans but contraindicated with personal/family history of MTC or MEN2. |
| eGFR / Creatininekidney function |
CLINICALeGFR >60 |
FLOW trial confirms renal protection — but monitor in CKD patients. Dehydration from GI side effects can transiently affect kidney function. |
08 / CYCLE PROTOCOL
Administration Schedule
DURATION
Ongoing — Maintenance Drug
LONG-TERM USE
Semaglutide is a maintenance medication — weight regain occurs if discontinued (average 2/3 of lost weight returns within 1 year). Current medical guidance treats it as chronic therapy, similar to blood pressure or cholesterol medications.
CYCLING APPROACH
Some compounding protocols cycle: 24 weeks on at full dose → 8 weeks at reduced maintenance (0.5–1mg) → reassess. Not standard of care but used in cost-management protocols.
LEAN MASS PROTECTION
Up to 40% of weight loss on GLP-1s alone may be lean mass (muscle). Mitigate with: ① Protein target ≥1.6g/kg/day ② Resistance training 3×/week ③ Consider adding BPC-157 for tissue integrity or a GH secretagogue to preserve muscle.
OPTIMAL STACK
Semaglutide + AOD-9604 500mcg AM (direct lipolysis) + MOTS-c 5mg AM (mitochondrial efficiency). Triple metabolic mechanism: appetite suppression + lipolysis + cellular energy optimization.
REQUIRES
Reconstitution with BAC water · Precise dosing with Apex V3 Pen · Refrigeration post-reconstitution · Weekly injection schedule
⚠ Research reference only. Compounded semaglutide is not equivalent to FDA-approved branded formulations in terms of regulatory status. Consult a licensed prescriber. Information sourced from published clinical trial data including STEP, SUSTAIN, SELECT, FLOW, and ESSENCE trial series.